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Enlarged vestibular aqueduct (EVA) is one of the most commonly identified inner ear mal-
formations in hearing loss patients including Pendred syndrome. While biallelic mutations of
the SLC26A4 gene, encoding pendrin, causes non-syndromic hearing loss with EVA or
Pendred syndrome, a considerable number of patients appear to carry mono-allelic mutation.
This suggests faulty pendrin regulatory machinery results in hearing loss. Here we identify
EPHA2 as another causative gene of Pendred syndrome with SLC26A4. EphA2 forms a protein
complex with pendrin controlling pendrin localization, which is disrupted in some pathogenic
forms of pendrin. Moreover, point mutations leading to amino acid substitution in the EPHA2
gene are identified from patients bearing mono-allelic mutation of SLC26A4. Ephrin-B2 binds
to EphA2 triggering internalization with pendrin inducing EphA2 autophosphorylation weakly.
The identified EphA2 mutants attenuate ephrin-B2- but not ephrin-A1-induced EphA2
internalization with pendrin. Our results uncover an unexpected role of the Eph/ephrin
system in epithelial function.
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The inner ear comprises a fluid-filled epithelial tube within aspiral space of the temporal bone. Inner ear malformation,such as enlarged vestibular aqueduct (EVA), is a char-
acteristic feature of Pendred syndrome, an autosomal recessive
disorder defined by hearing loss and goitre. Pendrin, also known
as sodium-independent chloride/iodide transporter, is an anion
exchanger protein that in humans is encoded by the SLC26A4
gene (solute carrier family 26, member 4)1–4. Pendrin was iden-
tified as a causative gene of Pendred syndrome1 and non-
syndromic hearing loss with EVA5. Various mutations in the
SLC26A4 gene associated with Pendred syndrome and non-
syndromic hearing loss with EVA have been identified6. While
Pendred syndrome patients do not exhibit serious symptom in
the kidney4, pendrin is predominantly expressed in the inner ear,
thyroid and kidney4. Some reported mutations on SLC26A4 cause
an impaired pendrin transporter function, others affect protein
folding, localization, or trafficking of pendrin6. Roughly 50–80%
of patients with EVA, have mutations in SLC26A47–9. Genetic
inactivation of Slc26a4 in mice established a causative role of
pendrin on inner ear dysfunction10. Although Pendred syndrome
is autosomal recessive, mono-allelic mutations of SLC26A4 are
often found in patients who are diagnosed with Pendred syn-
drome or non-syndromic hearing loss with EVA. Moreover, some
patients diagnosed with Pendred syndrome do not carry any
mutations of the SLC26A4 gene9. These observations suggest that
compromised pendrin regulatory machinery may result in hear-
ing loss, however, the regulator of pendrin remains elusive.
Eph receptors constitute the largest family of receptor tyrosine
kinases (RTKs) and interact with plasma-membrane-bound ephrin
ligands. Ephrins are divided into two subclasses, A subclass
(ephrin-A1-A5 in mammals), which are tethered to the cell
membrane by GPI-anchor, and B subclass (ephrin-B1-B3), which
are characterized by a transmembrane domain, followed by a short
cytoplasmic domain. Ephs are divided on the basis of sequence
similarity and ligand affinity into A (EphA1-A8 and A10) and B
(EphB1-B4 and B6) subclasses11. In the nervous system, Ephs are
known to be involved in axon guidance, neural crest cell migration,
compartment boundary formation and synapse formation12–15.
Ephs and their ligands also play important roles in vascular
development16,17. We have previously shown that ephrin-B2 and
EphBs binding regulate vascular morphogenesis. EphB/ephrin-B2
regulates vascular endothelial growth factor receptor (VEGFR) 2
and 3 internalization in endothelial cell18,19, suggesting functional
roles of Eph/ephrins in transmembrane protein localization. Eph/
ephrin interactions also govern the compartmentalization of cells
in epithelial tissue formation. Loss of ephrin-B2 in the epithelium
results in abnormal morphology of the inner ear20.
Here we identify EPHA2 as another causative gene of Pendred
syndrome with SLC26A4. Pendrin is identified as a binding partner
of EphA2. EphA2 knock out (KO) mice exhibit abnormal struc-
tures in epithelial tissues with mislocalization of pendrin, including
in the inner ear and thyroid. Given the phenotypic similarity of
inner ear epithelial ephrin-B2 deficient mice with pendrin loss of
function mice20, we re-examine the binding of ephrin-B2 with
EphA2. Although it is assumed that the ligands of class-A Eph
receptors are generally ephrin-As, we find that ephrin-B2 forms a
complex with EphA2. Stimulation of EphA2 with ephrin-B2
induces internalization of EphA2 and pendrin from the plasma
membrane leading to weaker autophosphorylation of EphA2 than
that with ephrin-A1. We find that a subset of mutated forms of
pendrin identified from Pendred syndrome patients do not bind to
EphA2 and is not regulated after stimulation of EphA2 with
ephrin-B2. Moreover, we identify EphA2 mutations in patients
diagnosed with non-syndromic hearing loss with EVA carrying
mono-allelic mutation of SLC26A4. Induction of the identified
EphA2 mutations reveals a compromised binding ability of EphA2
with ephrin-B2, but not ephrin-A1. As a result, ephrin-B2 induced
pendrin internalization is impaired. Our result reveals an unex-
pected relationship between the Eph/ephrin system and Pendred
syndrome.
Results
Identification of pendrin as a binding partner of EphA2.
EphA2 is highly expressed in epithelial cells in vitro and in vivo21,22.
In the kidney, immunoreactive signal against an EphA2 antibody
was confirmed in the lectin Dolichos biflorus agglutinin (DBA)
positive collecting duct (Supplementary Fig. 1a). Strong expression
of EphA2 in the basement membrane of the kidney epithelium in
the collecting duct was observed, which was diminished in kidney
sections from EphA2 knock out mice (Supplementary Fig. 1b, c)23.
Interestingly, a specific signal corresponding to EphA2 was also
seen in dot-like structures at the apical region of the epithelial cells
(Supplementary Fig. 1c). To gain further insight into the role of
EphA2 in epithelial cells, we carried out an interactome analysis of
EphA2. Immunoprecipitation of EphA2 from the mouse kidney
tissue using a specific antibody against EphA2 was examined.
Western blotting analysis has shown that 80% of total EphA2 in the
lysate was precipitated (Fig. 1a). After confirmation of specific
precipitation by silver staining (Fig. 1b), the eluted proteins were
analyzed by liquid chromatography with tandem mass spectro-
metry (LC-MS/MS), compared to an IgG control using label free
quantification. Given the important role of Eph/ephrin system as a
regulator of co-receptors18,19,24,25, we focused on transmembrane
proteins for further analysis. Among them, Slc26a4 (pendrin) pro-
tein was identified with the highest enrichment (Fig. 1c). To con-
firm the interaction of EphA2 and pendrin, a tagged version of both
proteins was overexpressed in HEK293T cells. When myc-tagged
pendrin was immunoprecipitated with an anti-myc-tag-antibody,
V5-EphA2 was co-precipitated (Supplementary Fig. 1d). Moreover,
the intracellular domain of EphA2 with the transmembrane domain
was co-precipitated with myc-tagged pendrin but not a construct
containing the extracellular domain of EphA2 with the trans-
membrane domain (Supplementary Fig. 1e). In addition to its
expression in the kidney, pendrin is known to be expressed at the
apical surface of the cells in the spiral prominence of the cochlear
duct in the inner ear and in the follicular cells in the thyroid26–28.
Pendrin was co-immunoprecipitated with EphA2 from both the
inner ear and thyroid lysates as well as from kidney lysates of
control mice but not those of EphA2 KO mice (Fig. 1d). Interest-
ingly, immunoreactive signal against EphA2 antibody was restricted
to the apical surface of the cells at the spiral prominence of the
cochlear duct in the inner ear (Fig. 1e), while it was observed at both
the apical and basal membrane of the follicular cells in the thyroid
(Fig. 1f).
EphA2 KO mice show pendrin mis-localization. Given the fact
that EphA2 was identified as a binding partner of pendrin, the
phenotype of EphA2 KO mice was reanalyzed in the inner ear and
the thyroid. Although overt structural changes, such as those seen
in Slc26a4 KO mice10, were not observed in the overall EphA2 KO
mice cochlea with micro-CT scan, the size of the cochlear duct
was significantly enlarged (Fig. 2a, b). H&E staining of the inner
ear revealed a decreased thickness of intermediate cell layer of the
stria vascularis in EphA2 KO mice, which consisted of three layers
of cells; marginal, intermediate, and basal cells (Fig. 2c–e).
Additionally, we found EphA2 KO mice showed obvious goitre
and thyroid hypertrophy (Supplementary Fig. 2a, b). H&E
staining of thyroid glands further confirmed an enlarged follicle
lumen area (Fig. 2f, g).
Next, we carried out immunostaining with an anti-pendrin
antibody in the inner ear, the thyroid and the kidney. Pendrin
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Membrane localization FALSE TRUE
Fig. 1 Identification of pendrin as an interacting protein of EphA2. a, b Immunoprecipitation of EphA2 from kidney lysate. Specific precipitation of EphA2
was confirmed by western blotting analysis (a) and by silver staining (b) of precipitated protein compared to IgG control. Indicated numbers in a represent
relative amount of precipitated EphA2 and EphA2 passed thorough immunoprecipitation compared to input (pass). c Identification of pendrin by label free
quantification in mass spectrometry-based protomics analysis of EphA2 immunoprecipitate as compared to IgG control. Pendrin is the protein with the highest
enrichment among membrane localized proteins. The ratio distribution of proteins identified is shown as a kernel density estimate. Localization of
transmembrane proteins in the distribution is indicated red in the rug. d Confirmation of the protein complex by immunoprecipitation using an anti-EphA2
antibody. Precipitated proteins from the kidney, the thyroid and the inner ear from control and EphA2 KO mice were analyzed by western blotting analysis with
the EphA2 and the anti-pendrin antibodies respectively. e Immunostaining of the inner ear using anti-EphA2 specific antibody (green or gray, arrowhead) with
phalloidin (red, F-actin) and DAPI (blue, nucleus). The specificity of the signal against EphA2 was confirmed in the EphA2 KO inner ear. SL spiral ligament, SV
stria vascularis, SP spiral prominence. f Immunostaining of the thyroid using anti-EphA2 specific antibody (green) with phalloidin (red, F-actin) and DAPI (blue,
nucleus). The specific signal of EphA2 was confirmed in the EphA2 KO thyroid. The strong signal of EphA2 was observed at basal membrane (arrow). Although
the signal is weak, EphA2 expression was also confirmed at apical surface (arrowhead). Source data are provided as a Source Data file.
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Follicle lumen area (μm2/100)
Fig. 2 Morphological analysis of EphA2 KO mice phenotype in the inner ear and thyroid. a View of the inner ear of control (upper panels) and EphA2 KO
mice (lower panels) visualized by µCT. Arrows in the sagittal section indicate the lumen in the cochlea. b Lumen volume was quantified. Lines indicate
mean value from three animals with SD. **p < 0.01 by student t-test. c–e Thickness of stria vascularis in the EphA2 KO mice was reduced compared to that
in control mice. c H&E staining of the inner ear are shown. Dot-line indicates the boarder of cell layers. d SV was consisted of mainly three cell types,
maginal cells, intermedia cells and basal cells as shown in (d). H&E staining of the inner ear revealed a decreased thickness of the intermedia cell layter in
EphA2 KO mice. e Average data from 4 animals are presented. Lines indicate mean value from four animals with SD. **p < 0.01 by student t-test. f, g EphA2
KO mice exhibited Thyroid goitre. H&E staining of thyroid sections are shown in (f). Proportion of follicle lumen area in control and EphA2 KO mice is
presented in the graph (g). Mean ± SD.; one-way ANOVA; ****p < 0.0001, ***p < 0.001, **p < 0.01. Source data are provided as a Source Data file.
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expression was restricted to the apical surface of epithelial cells of
the spiral prominence in the cochlea in control mice, meanwhile
it was delocalized from the apical surface and observed as dot-
like structures in EphA2 KO mice (Fig. 3a). Moreover, mis-
localization of pendrin from the apical surface to the intracellular
region was also observed in follicle cells in the thyroid of EphA2
KO mice (Fig. 3b). In the kidney, pendrin localization was
observed on the apical surface of epithelial cells in the renal tube
(Fig. 3c). Conversely, pendrin was found in an epithelial-epithelial
junctional pattern and intracellular vesicle like structures in the
EphA2 KO mice as well as disrupted apical surface staining
(Fig. 3c). These results indicate that EphA2 controls pendrin
localization in vivo. As the loss of pendrin expression in the
inner ear is known to lead to reduced expression of KCNJ10
protein, presumably causing deafness26, KCNJ10 expression in
stria vascularis was examined in EphA2 KO mice. The signal
corresponding to KCNJ10 was reduced in EphA2 KO mice
(Fig. 3d, e), suggesting a functional relationship between EphA2
and pendrin.
Ephrin-B2 is a ligand of EphA2. A recent study has shown
that inner ear epithelial cell specific Efnb2, the gene encoding
ephrin-B2, deficient mice exhibit vestibular-behavioral dysfunc-
tion and signs of abnormal endolymph homeostasis, which is
often seen in Pendred syndrome patients29. Ephrin-B2 is required
for the growth and morphogenesis of the endolymphatic sac and
duct of the inner ear20. Although the EphA2 receptors are known
to be activated by ephrin-A but not ephrin-B ligands30, we re-
examined the relationship between ephrin-B2 and EphA2. While
the ligands of EphAs are assumed to be ephrin-As, EphA4 has
been shown to bind to ephrin-B2. The crystal structure of the
EphA4 ligand-binding domain in complex with ephrin-B2 has
already been resolved (Fig. 4a)31. When the structure of EphA2
was superimposed to EphA4 in the complex with ephrin-B2, we
hypothesized that EphA2 could possibly bind to ephrin-B2
(Fig. 4a). Prompted by this prediction, we immunoprecipitated
ephrin-B2 from mouse kidney lysate and confirmed that ephrin-
B2 was co-precipitated with EphA2 from kidney lysate of control
mice but not that of EphA2 KO mice (Fig. 4b). Next, we incubated
soluble ephrin-B2 extracellular domain-Fc fusion protein with
MDCK II cell lysate and found that endogenous EphA2 was
precipitated with the extracellular domain of ephrin-B2 (Fig. 4c).
To confirm the interaction of EphA2 with ephrin-B2, we
calculated the Kd value between extracellular domains of the
ephrin-B2 and the EphA2. The fc-fusion protein of the EphA2
extracellular domain was immobilized onto the ELISA plate and
binding of that of ephrin-B2 was examined. The Kd value
between ephrin-B2 and EphA2 was 85 nM (Supplementary
Fig. 3a), while that between EphA2 and ephrin-A5, the classic
ligand of EphA2 was 2 nM (Supplementary Fig. 3b). The binding
of ephrin-B2 with EphA4 as a ligand has also been analyzed with
a previous observation by Bowden et al. determining the Kd
values of EphA4/ephrin-B2, EphA4/ephrin-A4, and EphA4/
ephrin-A5, respectively32. The Kd value of EphA4/ephrin-B2 was
10.8 μM, which ~30 times greater than that of EphA4/ephrin-A5
(Kd= 360 nM) and 300 times greater than that of EphA4/ephrin-
A4 (Kd= 36 nM). Thus, the Kd value of EphA2/ephrin-B2 was
within a reasonable range (Supplementary Fig. 3a, b)32.
The stimulation of RTKs by their ligand proteins induces
receptor dimerization and auto-phosphorylation33. Consistent with
previous findings, stimulation of MDCK II cells expressing EphA2
with ephrin-A1 extracellular domain FC-fusion protein, the classical
ligand of EphA2, promoted auto-phosphorylation of EphA2 at
Tyr594 in 15min, which was sustained at least up to 2 h (Fig. 4d, e).
The level of EphA2 auto-phosphorylation induced by ephrin-B2
was weaker than that by ephrin-A1, but observed in 15min after
stimulation (Fig. 4d, e). Under these conditions, treatment of the
cells with human Fc failed to induce EphA2 auto-phosphorylation
(Fig. 4d, e).
After stimulation with ligands, RTKs are internalized and
transported to early endosome33. Both ephrin-A1 and ephrin-B2
triggered internalization of cell surface EphA2 in a time dependent
manner (Fig. 4f, g). Interestingly, cell surface pendrin was also
internalized upon both ephrin-A1 and ephrin-B2 stimulation
(Fig. 4f, h). Consistent with the in vivo observations (Fig. 3a–c),
knock down of EphA2 reduced surface presentation of pendrin.
Under the condition, cell surface pendrin was not internalizad by
ephrin-B2 (Supplementary Fig 3c, d). Furthermore, we observed
co-localized immunoreactive signal corresponding to ephrin-B2,
phospho-EphA2 and EEA1, a marker of early endosomes, 2 h after
ephrin-B2 stimulation (Supplementary Fig. 3e, f). In addition, we
have confirmed that immunoreactive signal corresponding to the
anti-ephrin-B2 antibody was colocalized with that to the anti-
EphA2 antibody in the inner ear (Supplementary Fig. 3g). These
results suggest an important role of ephrin-B2 as an inducer of
EphA2 endocytosis with the transmembrane binding partner,
pendrin, while its effect is weaker than that of ephrin-A1.
Aberrant regulation of pathogenic forms of pendrin via
EphA2. Several amino-acid substitutions of pendrin have been
identified from Pendred syndrome patients as well as non-
syndromic hearing loss patients with EVA. To gain further insight
into the relationship between EphA2 and pendrin, we examined
the interaction of pathogenic forms of pendrin with EphA2.
Among reported mutations, introduction of some identified
mutations including pendrin Pro123 to Ser (P123S), Val 138 to
Phe (V138F), Leu236 to Pro (L236P), Ala372 to Val (A372V),
Asn392 to Tyr (N392Y), Thr416 to Pro (T416P), Leu445 to Trp
(L445W), Gln446 to Arg (Q446R), Gly497 to Ser (G497S), Val653
to Ala (V653A), Ser666 to Phe (S666F), Gly672 to Glu (G672E),
Thr721 to Met (T721M), and His723 to Arg (H723R) have been
found to be delocalized from the plasma-membrane to the cytosol
in cultured cells (Supplementary Fig. 4)6,34–38. When these
pathogenic forms of pendrin were transfected and immunopre-
cipitated with the EphA2 cytoplasmic domain containing trans-
membrane domain, myc-pendrin A372V, L445W, Q446R, and
G672E were not co-immunoprecipitated with EphA2 (Fig. 5a, b).
To gain further insight into the role of EphA2 on pendrin
regulation, pendrin A372V, L445W, Q446R or G672E was co-
overexpressed with EphA2. The cells were transfected with cDNAs
of encoding myc-pendrin diease forms with that of EphA2, and the
non-permeable cells were stained with an anti-myc antibody. While
signal corresponding to myc-pendrin was observed in ~65% of cells,
ratio of V5-pendrin A372V, L445W, Q446R, or G672E positive cells
was significantly decreased (Supplementary Fig. 5a, b). Under these
conditions, co-expression of EphA2 did not affect protein expression
levels of these pathogenic forms of pendrin (Fig. 5a) but partially
restored membrane localization of myc-pendrin A372V, L445W or
Q446R (Supplementary Fig. 5a, b). On the other hand, EphA2
overexpression did not affect localization of G672E.
The substitutions of Leu117 to Phe (L117F), Ser166 to Asn
(S166N), and Phe335 to Leu (F335L), identified in Pendred
syndrome patients, do not affect their membrane localization6,36.
Given the reported normal function of pendrin L117F and
pendrin S166N as an anion exchanger6,36, compromised regula-
tory machinery of pendrin function may cause the observed
symptoms. To examine whether EphA2 is involved in dysfunction
of pendrin caused by these amino acid substitutions, the effect of
pendrin L117F, pendrin S166N, and pendrin F355L mutations on
EphA2 interaction and internalization was examined. While the
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Fig. 3 Compromised localization of pendrin in EphA2 KO mice. a Immunostaining of pendrin in the inner ear of control and EphA2 KO mice. Green,
pendrin; red, actin; blue, DAPI. Arrowheads indicate the immunoreactive signal corresponding to pendrin. b Immunostaining of pendrin in the thyroid
of control and EphA2 KO mice. Green, pendrin; red, actin; blue, DAPI. Arrowheads indicate the immunoreactive signal corresponding to pendrin.
c Immunostaining of pendrin in the kidney of control and EphA2 KO mice. Green, pendrin; red, actin; blue, DAPI. Arrows and arrowheads indicate the
immunoreactive signal corresponding to pendrin. d Immunostaining of KCNJ10 in the inner ear of control and EphA2 KO mice. KCNJ10 expression in stria
vascularis shown in green was reduced in EphA2 KO mice. e Average data from four animals are presented. Lines indicate mean value from 4 animals with
SD. ***p < 0.001 by Studentʼs t-test. Source data are provided as a Source Data file.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-15198-9
6 NATURE COMMUNICATIONS |         (2020) 11:1343 | https://doi.org/10.1038/s41467-020-15198-9 | www.nature.com/naturecommunications
amount of co-precipitated pendrin mutants with EphA2 was
comparable to that of wild type (wt) pendrin (Fig. 5c, d), the
S166N mutant failed to be internalized after ephrin-B2 stimulation
(Fig. 5e, f). Taken together, these results further demonstrate that
EphA2 could control both pendrin recruitment to the plasma
membrane and pendrin exclusion from the plasma membrane.
EPHA2 mutations in pendred syndrome patients. Among
sensorineural hearing loss patients EVA or the Pendred syndrome
patients, a considerable number of patients carry one copy of the
mutation on the SLC26A4 gene, therefore a compromised pendrin
regulatory machinery may be involved in the pathogenesis of the
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syndrome, direct sequencing of the EPHA2 gene in 40 Japanese
hearing loss patients with EVA carrying mono-allelic mutation of
SLC26A4 were examined. While mutation of ~70 genes causing
hearing loss were previously identified as a human nonsyndromic
deafness gene39, they were not identified in these patients40. On the
other hand, two missense mutations of the EPHA2 gene were
identified in two families, SLC26A4: c.1300G>A (p.434A>T),
EPHA2: c.1063G>A (p.G355R) and SLC26A4: c.1229C>A
(p.410T>M), EPHA2: c.1532C>T (p.T511M) (Fig. 6a, b). These
EPHA2 mutations were predicted to be pathological by several in
silico prediction software programs (Supplementary Table 1). The
patient carrying c.1300G>A of SLC26A4 was previously reported41.
She is 22-years-old and presented congenital bilateral sensorineural
hearing loss, goitre and skin disorders, while her brother, sister and
parents were healthy and did not show such symptoms (Fig. 6a).
Another patient carrying c.1229C>A of SLC26A4 is 14-years-old
and exhibited progressive, symmetrical sensorineural hearing loss
and goitre (Fig. 6c). Her mother was healthy and carries a mutation
of the EPHA2 gene but not the SLC26A4 gene (Fig. 6b). A temporal
bone CT scan of the patient revealed an EVA (Fig. 6d). Previously,
a haplotype of 12 uncommon variants upstream of the SLC26A
gene was identified to presumably cause the syndrome in patients
carrying one coding mutation of the SLC26A gene in the United
States and Denmark, while the EVA-associated haplotype (CEVA)
is rare in Asian polulations42,43. Consistently, these variants were
not identified from these two patients.
Mutated EphA2 affects its ligand-binding specificity. The
ligand binding domain (LBD), Cysteine-rich domain (CRD) and
fibronectin 1 (FN1) domain of EphA fold into a rigid, rod-like
structure with little interdomain flexibility. Conversely, the con-
nection between FN1 and FN2 is flexible. Interestingly, the
EphA2 mutations identified in the patients, Gly355 and Thr511,
are located in proximity of the linker region between Sushi/EGF
domain and FN1, and between the FN1 and FN2, respectively
(Supplementary Fig. 6a)44. A crystal structure of ephrin-A5 and
EphA4, which has high sequence homology with EphA2, has
been reported45. An extracellular domain of EphA2 with EphA4
with identified mutations is presented (Supplementary Fig. 6a).
Interestingly the sites of the identified EphA2 mutations are
conserved among all the other human EphA and EphB. More-
over, Gly355 is conserved in C. elegans Eph, while Thr511 is
conserved in Drosophila Eph, Dek (Supplementary Fig. 6b).
These facts suggest an essential role of these amino acids on Eph
function that might be conserved throughout evolution. To
examine whether these mutations affect the ligand-binding spe-
cificity of EphA2 to ephrin-A and ephrin-B, a pull down assay
was performed with HEK293T cells due to their low level of
endogenous EphA2 expression (Supplementary Fig 7a, b)15.
While tagged versions of EphA2 G355R and EphA2 T511M were
effectively precipitated with Fc-fusion ephrin-A1 compared to
EphA2 WT, Fc-fusion ephrin-B2 failed to pull down EphA2
G355R and T511M (Fig. 7a). Consistently, internalization of
EphA2 G355R and EphA2 T511M with pendrin induced by
ephrin-B2 but not ephrin-A1 was suppressed (Fig. 7b, c). On the
other hand, the mutated forms of EphA2 did not affect their
ability to bind to pendrin (Fig. 7d).
Discussion
Proper and polarized localization of transporters in cells is
essential for their function. Various previously identified pendrin
mutations cause pendrin cytoplasmic localization. A subset of
these mutations, such as H723R, are known to cause mis-folding
of the protein, leading to accumulation in the endoplasmic
reticulum35,46. Low temperature incubation and salicylate treat-
ment of cultured cells, which are thought to help with protein-
folding processes, rescues the membrane localization of H723R35.
On the other hand, mis-localization of pendrin A372V from the
plasma membrane is not restored by these treatments35, sug-
gesting these mutations may affect pendrin trafficking from the
Golgi to the plasma membrane but not protein-folding. Here, we
found that pendrin A372V, L445W, Q446R, and G672E did not
bind to EphA2. Given the fact that loss of EphA2 disturbs pen-
drin apical localization in vivo and cell surface presentation
in vitro, the binding of pendrin with EphA2 might be critical for
pendrin recruitment to the apical membrane in the inner ear and
the thyroid. Thus, loss of the ability of pendrin to bind EphA2
may cause delocalization of pendrin from the plasma membrane.
Additionally, we examined the binding ability of EphA2 to four
membrane located forms of mutated pendrin. None of the
mutants had impaired interaction with EphA2. However, S166N,
which is known to have an intact transporter activity and
membrane localization in cultured cells36, showed compromised
endocytosis after ephrin-B2 stimulation. Multiple types of ephrin-
A are expressed in the inner ear during development47, mean-
while inner ear epithelial cell specific Efnb2 KO mice exhibit
EVA-like malformation20. While the function of ephrin-A5 in the
inner ear was investigated48, no reports have shown that any
ephrin-A single KO mice show inner ear malformation. These
observations suggest an indispensable role of ephrin-B2 in the
morphology of the inner ear. In the EphA2 KO mice kidney,
pendrin was also observed at the epithelial-epithelial contact sites.
Interestingly, Eph/ephrin interaction would presumably occur at
the cell-to-cell contact sites. Thus, EphA2 might also be impor-
tant to exclude pendrin from cell-to-cell contact sites and con-
tributes to the restricted pendrin localization at the apical surface
(Fig. 3f). Furthermore, we have also identified two EPHA2
mutations from patients carrying mono-allelic SLC26A4 muta-
tion. The induction of mutations, identified in the patients car-
rying the mono-allelic SLC26A4 mutation, into EphA2 impaired
its binding ability to ephrin-B2 but not ephrin-A1. While the
effect of the substitution of pendrin Ala434 to Thr on molecular
activity or localization is not known, the substitution of Thr410 to
Met is known to result in mis-localization of pendrin from the
Fig. 4 Ephrin-B2 is a ligand of EphA2. a Overall structure of the EphA2/ephrin-A1, EphA4/ephrin-B2, and EphA2/ephrin-B2 complexes. Protein Data Bank
codes are indicated. In addition to a loose fit of the ephrin-B2 G-H loop in the EphA4 ligand-binding channel, a second contact region in the EphA4-ephrin-
B2 interface involving extensive surface polar contacts may form binding of EphA4 to ephrin-B2 (i). The side chain hydrogen bond between Gln40 of
EphA4 and Gln106 of ephrin-B2 (ii) and the side chain salt bridge between Glu42 and Lys109 of ephrin-B2 (i) might form the binding of ephrin-B2 and
EphA4. b Immunoprecipitation of ephrin-B2 with EphA2. Precipitated proteins analyzed by immunoblot. c Pull-down analysis using ephrin-B2-Fc fusion
protein. Co-precipated EphA2 is shown by immunoblot analysis. d The effect of ephrin-B2 and ephrin-A1 stimulation on EphA2 autophosphorylation.
Cultured MDCK II cells were stimulated with ligands for the indicated time. e Relative amount of phospho-EphA2 is shown. Mean ± SEM.; one-way
ANOVA; ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05; (n= 3). f The effect of ephrin-B2 and ephrin-A1 stimulation on EphA2 and pendrin
internalization. Samples were analyzed by western blotting with indicated antibodies. e Relative amount of cell surface EphA2 (g) or pendrin (h) is shown.
Mean ± SEM.; one-way ANOVA; *p < 0.05; (n= 3). Source data are provided as a Source Data file.
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Fig. 5 Some pathogenic variants of pendrin are not affected by EphA2/ephrin-B2 regulation. a, b Immunoprecipitation of EphA2 with mutated pendrin.
myc-pendrin A372V, L445W, Q446R, G672E were not co-immunoprecipitated with EphA2. Densitometric quantifications are shown (b). Mean ± SEM; one-
way ANOVA with Bonferroni post hoc analyses; *p < 0.05; (n= 3). c, d Immunoprecipitation of EphA2 with mutated pendrin. Immunocomplex of myc-pendrin
L117F, S166N and F355L was not affected. Densitometric quantifications are shown (d). Mean ± SEM; (n= 3). e, f Internalization of EphA2 and mutated pendrin
triggered by ephrin-B2 stimulation. Pendrin S166N was not internalized after ephrin-B2 stimulation while EphA2 and other mutated pendrins were not affected.
f Relative amount of cell surface pendrin is shown. Mean ± SEM; one-way ANOVA; **p < 0.01; *p < 0.05; (n= 3). Source data are provided as a Source Data file.
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plasma membrane and loss of iodide efflux ability6. We could not
access the sequence of the patient’s father, but her healthy mother
carried the mono-allelic EPHA2 mutation and did not have any
mutation in the SLC26A4 gene implying a synergistic effect of dual
mutations on EPHA2 and SLC26A4 on symptoms. Mono-allelic
EPHA2 mutation with the hetero-pendrin mutation may cause
pendrin recruitment to the basolateral region in the patients,







SLC26A4 : c.[=];[=]  
EPHA2 : c.[1532C>T];[=]  
SLC26A4 : c.[1229C>A];[=]  
EPHA2 : c.[1532C>T];[=]  
SLC26A4 : c.[1300G>A];[=]  
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Fig. 6 Identification and characterization of EphA2 mutation from hearing loss patients with EVA. a, b Pedigree chart of the patients carrying mono-
allelic EPHA2 and SLC26A4 mutations. c Audiograms of the patient with mono-allelic EPHA2 p.T511M and SLC26A4 p.T410M mutations. d Temporal bone
computed tomography (CT) scan of the patient with mono-allelic EPHA2 p.T511M and SLC26A4 p.T410M mutations. The arrow indicates the vestibular
aqueduct in the patient and the healthy control.
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Fig. 7 Identified EphA2 mutations affect its ability to bind ephrin-B2 but not ephrin-A1. a Pulldown assay using ephrin-A1 or ephrin-B2 Fc fusion proteins
with V5-EphA2 and V5-mutated EphA2. Input and pulldown protein with Fc fusion proteins are shown by immunoblot analysis with anti-V5 antibody.
Relative amount of pulled down EphA2 is shown below. Mean ± SEM.; two-way ANOVA; **p < 0.01; *p < 0.05; (wt, n= 6; mt, n= 3). b The effect of
identified mutations on ephrin-A1 and ephrin-B2 induced EphA2 internalization. After surface biotinylation, samples were analyzed by western blotting
analysis using an anti-V5 antibody. Relative amount of cell surface EphA2 is shown below. Mean ± SEM; one-way ANOVA; *p < 0.05; (n= 3). c The effect
of identified mutations on ephrin-A1 and ephrin-B2 induced pendrin internalization. After surface biotinylation, samples were analyzed by western blotting
analysis using an anti-pendrin antibody. Relative amount of cell surface pendirn is shown below. Mean ± SEM; one-way ANOVA; *p < 0.05; (n= 3).
d Immunoprecipitation of mutated EphA2 with pendrin. EphA2 mutations do not affect the binding ability of EphA2 with pendrin. Densitometric
quantifications are shown below. Mean ± SEM; (n= 3). Source data are provided as a Source Data file.
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causing functional deficiencies (Supplementary Fig. 8a). Although
pendrin localization might be controlled by a tissue-dependent
mechanism, our results may suggest at least two potential roles of
EphA2 in Pendred syndrome: (1) recruiting pendrin to the cell
surface (2) excluding membrane localized pendrin from the
basolateral region (Supplementary Fig. 8a). Pendred syndrome is
the congenital hearing loss, suggesting the importance of devel-
opment of the inner ear. The gene deletion of Efnb2 with a con-
stitutive cre driver line in the inner ear epithelial cells cause
malformation at E15.5 likewise Slc26a4 KO mice10,20. Thus, it is
likely that EphA2 KO mice may have the inner ear defects at
E15.5. Further analysis is warranted.
Given the fact that the identified amino acid substitutions,
G355R and T511M are not located in the LBD, it would be
interesting to reveal how these two mutations affect ligand-binding
specificity between ephrin-B2 and ephrin-A1 to EphA2. As the
substitutions replace relatively small residues with bulky residues, it
could greatly influence the structural flexibility or rigidity between
the surrounding domains. It is worthy noting that EphA2 has been
hypothesized to adopt distinct overall structures, “upright” or “flat”
with respect to the plasma membrane, depending on cluster den-
sity to exert different signaling49. Since ephrin-A and ephrin-B are
anchored to the plasma membrane in different ways and differ in
the distance from the membrane30, the identified mutations may
alter the preference of the overall EphA2 complex structure and
may explain the ligand-class-specific effect. Another interesting
model to be considered is the hypothetical hexameric form of the
EphA4/ephrin-B3 complex　reconstructed from crystal lattice
assembly, whose distinct asymmetrical conformation at FN1-FN2
linkage necessitates the flexibility in the region (Supplementary
Fig. 8b, c)44, while it would not be necessary for the trimer of the
EphA4/ephrin-A5 complex and for the dimer of the EphA2/
ephrin-A5 complex (Supplementary Fig. 8d, e). Some protomers of
EphA4 need to take on an extended FN1-FN2 conformation while
the other protomers bend at FN1-FN2 linkage to alter for all the
protomers to attach to the surface of flat membrane (Supple-
mentary Fig. 8c). While oligomerization interfaces are not com-
pletely conserved among EphAs and the above model of EphA4
does not necessarily support similar clustering of EphA2-ephrinB2,
distinct clustering structures imposed by ephrin-A and ephrin-B
and their differential requirement for the flexibility in domain-
linkage is another possible scenario.
Some of congenital deafness patients, such as Alport Syn-
drome, Marshall Syndrome, Stickler Syndrome, and Norrie dis-
ease, are associated with cataracts50–53. Interestingly, EphA2 is
also known as a causative gene of cataracts54. It has been shown
that homozygous deletion of EphA2 in the KST085 mouse line or
the C57Bl/6/129 mouse line backcrossed with the FVB/N back-
ground mice are reported to develop progressive cortical catar-
acts54. On the other hand, we did not observe cataracts in our KO
mice, which were generated and kept in the C57Bl/6/129 line.
This might be due to the different genetic background of mice.
Although the two patients carrying EPHA2 mutation identified
this study do not have cataracts, dominant pathogenic variants of
human EPHA2 have been reported and the subjects carrying
these variants have cataracts54. EphA2 KO mice are shown to
have more susceptibility to microbial infections55, however, we
did not observe any symptom related to this mouse phenotype in
the patients. Reported cataract-related EPHA2 mutations are
either located in the intracellular kinase domain or the SMA
domain, causing EphA2 loss of function. Conversely identified
EphA2 mutations affecting ligand class specificity of ephrins,
might cause more restricted effects. Given the broader effect of
EphA2 loss of function in such diseases, analysis of EPHA2
mutations in the patient might be interesting.
Methods
Mouse line. Experiments involving animals were conducted in accordance with
institutional guidelines and laws, and following the protocols approved by the local
animal ethics committees and authorities (University of Tokyo or Regierung-
spraesidium Darmstadt). EphA2 was targeted in ESCs via promoter trap experi-
ments using the reverse orientation splice acceptor (ROSA) β-Geo retro viral gene
trap vector. Insertion site for trap vector is located in the first intron of EphA223.
Knocked out alleles are shown in Supplementary Fig. 1b. These targeted ESCs were
then injected into blastocysts of fertilized C57BL/6 female mice and backcrossed for
five generations to generate the EphA2 knock-out (EphA2 KO) line. To maintain
the EphA2 knock-out mouse line, C57BL/6 EphA2 knock-out mice were cross with
129SV mice. Heterozygous transgenic mice did not display any obvious develop-
mental defects. Genotyping PCR amplifications were performed directly on alka-
line lysates of tail tips using REDTaq ReadyMix (SIGMA, R2523). The primers
used for genotyping were listed in Supplementary Table 2.
Human subjects and clinical evaluation. We studied 40 patients affected by
congenital sensorineural hearing loss with EVA. Computerized tomography scan
was used to diagnose EVA (according to the criteria of EVA: a diameter of >1.5
mm at the midpoint between the common crus and the external aperture), and
they were clinically well characterized by repeated auditory examinations. The
degree of SNHL ranged from severe or profound. Thyroid function tests were
performed for thyroid-stimulating hormone (TSH), free triiodothyronine (FT3),
free thyroxine (FT4), and thyroglobulin. The serum concentrations of thyroid
hormones were determined using the ECL-IA method. These studies were carried
out under the agreement of the patients after ethical approval by the ethics com-
mittee of Shinshu University School of Medicine and in accordance with the
Declaration of Helsinki. The written informed consent was obtained from those
patients.
Moleculor cloning. pCMV-Myc-pendrin was a kind gift from Professor Min Goo
Lee. pcDNA3.2-V5-EphA2 construction was achieved by using GatewayTM LR
ClonaseTM II Enzyme Mix (Invitrogen, 11791-020) according to the manufacturer’s
instructions; pDONR223-EphA2 (Addgene, 23926) and pcDNA3.2/V5-DEST
(Thermo Fisher, 12489019) were used as donor vector and destination vector.
FLAG-HA-pcDNA3.1-EphA2-1-558 and FLAG-HA-pcDNA3.1-EphA2-538-976
were subclone of EphA2 intracellular domain including transmembrane domain
(amino acid 1-558) and extracellular domain including transmembrane domain
(amino acid 538-976) into FLAG-HA-pcDNA3.1 backbone. The primers used for
domain cloning were shown in Suppementary Table 2. Point mutagenesis of pen-
drin and EphA2 were generated by using KOD Hot Start Mutagenesis kit (Merck
Millipore, Toyobo; 71086-3); the pcDNA3.2-V5-EphA2 and pCMV-Myc-pendrin
constructs were used as backbones. The primers used for point mutagenesis were
listed in Supplementary Table 2.
Cell culture and transfections. Madin-Darby Canine Kidney II cells (MDCK II;
ATCC #CRL-2936) were cultured in Minimum Essential Medium (MEM; Sigma)
with 10% fetal bovine serum (FBS; Biochrom GmbH), 1% Non-Essential Amino
Acid (NEAA; Gibco, Invitrogen), 100 IU/ml penicillin and 100 µg/ml streptomycin.
Human embryonic kidney 293 (HEK293; ATCC #CRL-1573) cells and human
embryonic kidney 293T (HEK293T; ATCC #CRL-3216) cells were cultured in
Dulbecco’s Modified Eagle Medium (DMEM; Sigma) with 10% FBS, 2 mM L-
glutamine (Gibco, Invitrogen), 100 IU/ml penicillin and 100 µg/ml streptomycin.
Plasmids and siRNA transfections into MDCK were carried out with
Lipofectamine 2000 (Invitrogen, 11668) using reverse transfection. To knock down
EphA2 in MDCK II cells, siRNA AUCACUGCCAAGUUGCCAGAUGCUU was
used. Plasmids’ transfections into HEK293T were carried out with polyethylenimine
(PEI; Polysciences Inc., 24765) transfection protocol. HEK293 T cells were seeded
onto 60mm dish one day before transfection, and cultured with DMEM (10% FBS)
for 12 h. Two micrograms of plasimd was added into 200 μl of 150 mM NaCl and
immediately mix with 200 μl of 150mM PEI-NaCl solution (200 μl of 100mM PEI
in 20ml of 150mM NaCl). After incubation for 10min at room temperature,
plasmid mixture was then added onto the cells and incubated for 24 h at 37 °C. Cells
were analyzed 24 h post transfection.
Immunoprecipitation from tissues and cultured cells. Cochleas were dissected
from wild type C57BL/6 mice at age of P5. Thyroids and kidneys were dissected
from wild type adult C57BL/6 mice. Minced tissues were immersed in 3 ml cold
RIPA buffer per gram of tissue (50 mM Tris- HCl, pH 7.4; 1% NP-40; 0.5% sodium
deoxycholate; 150 mM NaCl; 1 mM EDTA; Protease inhibitor cocktail, Sigma) and
were homogenized on ice. The lysates were then sonicated with ultrasonic
homogenizers (BANDELIN) for 5 × 5 s with 50% power. Tissues lysates were
centrifuged at 10,000 × g for 15 min and 60 μl of supernatants was taken as “input”
and boiled with 30 μl of 3× SDS sample buffer. The supernatants were mixed with
2 μg of anti-EphA2 antibody and 10 μl of dynabeads protein G (EphA2 immu-
noprecipitation) and incubated for overnight at 4 °C with rotation. Beads were
washed with RIPA buffer three times and the immunoprecipitates were analysed
with western blotting using specific antibodies.
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For cell immunoprecipitation, HEK293T cells were seeded into 60 mm dish,
and transfected with pcDNA3.2-V5-EphA2, FLAG-HA-pcDNA3.1-EphA2-1-558,
FLAG-HA-pcDNA3.1-EphA2-538-976, pCMV-Myc-pendrin and their
corresponding point mutants or control empty vectors using PEI transfection
protocol. 24 h after transfection, cells were washed once with ice cold PBS and
harvested with lysis buffer (50 mM Tris-HCl, pH 7.4; 1% Triton X-100; 150 mM
NaCl; 1 mM EDTA; Protease inhibitor cocktail, Sigma). The lysates were then
sonicated with bioruptor (Diagenode) at maximum power for 10 × 5 s. Cell lysates
were centrifuged at 10,000 × g for 15 min. The supernatants were mixed with 10 μl
bed volume of anti-c-Myc magnetic beads (Myc immunoprecipitation), or 15 μl
bed volume of anti-FLAG-M2 magnetic beads (Flag immunoprecipitation), and
incubated for 1 h at 4 °C with rotation. Beads were washed three times with lysis
buffer and the immunoprecipitates were analysed with western blotting.
Silver staining. After electrophoresis, gels were placed in 100 ml of fixative solu-
tion (50% MeOH, 20% ACOH) for 30 min and washed with 100 ml of 50% ethanol
for 3 × 30 min. Gels were then incubated with 100 ml of sensitizing solution
(0.129 g/l Na2S2O3) for 1 min, and wash for 3 × 20 s in 100 ml of ultrapure water.
For staining, 100 ml of impregnation solution (AgNO3) was applied to the gels for
20 min. The gels were washed with 100 ml of ultrapure water for 2 × 20 s. In all,
100 ml of developing solution (60 g/l Na2CO3; 37% HCOH/I; 4.3 mg/l Na2S2O3 ×
5 H2O) was added onto the gel and incubate for 5 min at room temperature with
gentle agitation on a rotary shaker. Once the desired band intensity was achieved,
immediately discard developer solution and add 10 ml of stopper solution (50%
MeOH, 10% ACOH) directly to the gel and gently agitated for 10 min. The gel was
washed with 100 ml of washing solution B (50% MeOH) for 2 × 30 min.
Surface biotinlaytion. Ephrin-A1 Fc chimera protein and ephrin-B2 Fc chimera
protein were first pre-clustered before adding onto cells. Pre-clustering was
achieved using 0.2 μg of goat anti-human IgG Fc (anti-Fc, Jackson Laboratories)
per μg of Fc-proteins (at a concentration of 10 μg/ml) for 30 min at room tem-
perature. Clustered Fc proteins were then added onto cells. MDCK II or
HEK293T cells were cultured in 60 mm dishes and washed with 3 ml of ice cold
washing solution (PBS containing 1 mM MgCl2 and 1 mM CaCl2) for three times.
Cells were treated with 1 ml of Sulfo-NHS-biotin (0.5 mg/ml in washing solution,
Thermo, #21217) at 4 °C for 1 h. Then cells were applied with 3 ml of stop solution
(100 mM glycine in PBS) for three times. To precipitate biotin-labeled surface
proteins, cells were treated with 800 μl of lysis buffer (25 mM Tris- HCl, pH 8.0; 1%
Triton X-100; 150 mM NaCl; 5 mM EDTA; Protease inhibitor cocktail, Sigma) for
15 min at 4 °C with rotation. Lysates were centrifuged at 10,000 × g for 15 min.
60 μl of supernatants was taken as “in put” and boiled with 30 μl of 3× SDS sample
buffer. Aliquots of supernatants were precipitated with 100 μl of streptavidin-
coated agarose beads (Invitrogen, S951) at 4 °C for 2 h with rotation. Beads were
then washed three times with lysis buffer and proteins were eluted with 60 μl of 1×
SDS sample buffer.
Recombinant Fc proteins pull down. MDCK II or HEK293T cells transfected with
mock, wild type or mutated EphA2 constructs were incubated with pre-clustered
ephrin-A1 Fc and ephrin-B2 Fc for 0, 1, and 2 h at 37 °C. The cells were then
washed with PBS for 2 times and were harvested with lysis buffer (50 mM Tris-
HCl, pH 7.4; 1% Triton X-100; 150 mM NaCl; 1 mM EDTA; Protease inhibitor
cocktail, Sigma). The lysates were then sonicated with Bioruptor (Diagenode). The
supernatants were mixed with 10 μl of dynabeads protein G (Fc protein pre-
cipitation) and incubated for overnight at 4 °C with rotation. Beads were washed
with lysis buffer three times and the precipitates were analysed with western
blotting using anti-V5 tag antibodies.
ELISA binding assay. ELISA binding assay was performed to determine the Kd
valules56. In short, EIA 96 well plates (Costar, Corning Inc.) were coated with
ephrin-A5 Fc or ephrin-B2 Fc fusion proteins (3 μg/ml) in 50 mM carbonate buffer
pH9.5 overnight at 4 °C, prior to blocking with 5% (w/v) BSA, 0,05% (v/v) Tween-
20 in PBS (PBST) for 1 h at room temperature. After three times washes with
PBST, diluted EphA2 Fc analyte was added and incubated ro 1 h at room tem-
perature. After three times washes with PBST, plates were incubated with bioti-
nylated 1F7 mAb (1 μg/ml) in PBS for 1 h at room temperature. After three times
washes with PBST, UltraStreptavidin-HRP (Thermo Fischer Scientific) dilute
1/500 in PBS was added and incubated 1 h at room temperature. After three times
wahs with PBST, final detection via the addition of OPD (SigmaFastTM) with the
end product was measured at OD492 nm.
Tissues and cells immunostaining. For inner ear immunostaining, inner ears
were first fixed with 4% paraformaldehyde (PFA) by injection through round
window. Next, inner ears were incubated in phosphate buffer (Wako Pure Che-
mical Industries, 167-14491) containing 10% EDTA overnight at 4 °C, followed by
dehydration with 30% sucrose. Samples were then embedded into OCT cryostat
sectioning medium and 10 μm crysections were made by Leica cryotome (Leica,
CM3050S). Sections were blocked in blocking buffer containing 4% FBS diluted in
PBS at room temperature for 1 h. Primary antibodies (anti-EphA2, 1/50, R&D
Systems AF1556; anti-pendrin, 1/50, Bio-Rad, 2150-1470; anti-KCNJ10, 1/50, BD
Biosciences, 555289; Phalloidin, Alexa-Fluor-647, 1/500, Invitrogen, A22287; anti-
ephrin-B2, 1/100, R&D Systems AF496), diluted in blocking buffer (2% FBS diluted
in PBS) were applied overnight at 4 °C. After washing, inner ear sections were
incubated with the corresponding Alexa-Fluor-coupled secondary antibody (Invi-
trogen, 1/500) in blocking buffer (1% FBS in PBS) for 2 h at room temperature.
Sections were flat-mounted using Fluromount-G (SouthernBiotech, 0100-01).
For kidney and thyroid immunostaining, mice were perfused with PBS and 4%
PFA respectively. The tissues were embedded in OCT and frozen immediately. The
rest of staining steps were the same as descried above. Primary antibodies (anti-
EphA2, 1/50, R&D Systems AF1556; anti-pendrin, 1/50, Bio-Rad, 2150-1470; lectin
Dolichos biflorus agglutinin, 1/500, Invitrogen, A22287) were used for kidney and
thyroid immunostaining.
For cells immunostaining, transfected or mock MDCK II cells were first
cultured on gelatin coated cover slides. Cells were washed with PBS once and fixed
in 4% PFA at room temperature for 10 min. After three times washing with PBS,
cells were treated with permeabilization buffer (0.1% Triton-X-100 in PBS) for 15
min and then blocked in blocking buffer (0.1% BSA in PBS) for 30 min at room
temperature. Primary antibodies (anti-EphA2, 1/50, R&D Systems AF1556; anti-
pendrin, 1/50, Bio-Rad, 2150-1470; anti-EEA1, 1/50, BD Biosciences, 555289;
Phalloidin, Alexa-Fluor-647, 1/500, Invitrogen, A22287) were applied overnight at
4 °C. After three times washing, slides were incubated with the corresponding
Alexa-Fluor-coupled secondary antibody (Invitrogen, 1/500) for 2 h at room
temperature. Slides were flat-mounted using Fluromount-G (SouthernBiotech,
0100-01).
To rescue mutated pendrin localization, 10 μg of V5-EphA2 and 5 μg of myc-
pendrin mutants were transfected into MDCK II cell. Non-permealibized cells were
stained with c-Myc antibody.
All immunostaining images were taken by Leica TCS SP8 and ZEISS LSM 710
confocal laser scanning microscopes. Images were analyzed by Volocity
6.3 software. The specificity of these antibodies was evaluated as shown in
Supplementary Table 3.
Cell lysis and western blotting. Cells were rinsed once with PBS, and harvested
with 1× SDS sampling buffer (50 mM Tris-HCl pH6.8, 2% SDS, 10% glycerol, 1%
β-mercaptoethanol, 12.5 mM EDTA, 0.02% bromophenol blue) and boiled at 95 °C
for 10 min. The protein samples were then subjected to immunoblot analysis using
indicated antibodies. Uncropped images are shown in Supplementary Fig. 9.
Mass spectrometry. Immunoaffinity purifications by anti-EphA2 antibody and
control IgG from adult wild type C57BL/6 mice kidneys were subjected in parallel
to In-gel digestion57. Five gel blocks were cut per sample and peptides finally
captured, cleaned and stored using STAGE tips58.
For mass spectrometry (MS) analysis, peptides were eluted from STAGE tips by
solvent B (80% acetonitrile, 0.1% formic acid), dried down in a SpeedVac
Concentrator (Thermo Fisher Scientific) and dissolved in solvent A (0.1% formic
acid). Peptides were separated using a nano-flow HPLC system (EASY-nLC,
ThermoFisher Scientific) and 20 cm, in-house packed C18 silica columns (1.9 µm
C18 beads, Dr. Maisch GmbH) coupled in line to a QExactive orbitrap mass
spectrometer (ThermoFisher Scientific) using an electrospray ionization source.
Peptides were subjected to a linearly increasing gradient concentration of solvent B
(90% acetonitrile, 1% formic acid) over solvent A (5% acetonitrile, 1% formic acid)
from 10% to 38% for 55 min and from 38% to 60% for 5 min, followed by washing
with 95% of solvent B for 5 min and re-equilibration with 5% of solvent B. Full MS
spectra were acquired in positive mode and a mass range of 300 to 1650 m/z with a
resolution of 70,000 at 200 m/z. The ion injection target was set to 3 × 106 and the
maximum injection time limited to 20 ms. Ions were fragmented by high-energy
collision dissociation (HCD) using an isolation window width of 1.8 m/z, a
normalized collision energy of 27 and a ion injection target of 5 × 105 with a
maximum injection time of 120 ms. The resulting tandem mass spectra (MS/MS)
were acquired with a resolution of 35,000 at 200 m/z using data dependent mode
with a loop count of 10 (top10). The instrument was further configured to use a
minimum AGC target of 5 × 102 and an intensity threshold of 4.23 × 103 for
fragmentation spectra and exclude precursor ions with a charge state of 1, as well as
unassigned charge states and members of already targeted isotope clusters and to
use a dynamic exclusion time of 20 s.
Mass spectrometric raw data were caluculated using the MaxQuant/Andromeda
suit of algorithms (v. 1.5.2.8)59; against the human UniprotKB database (88703
entries; The UniProt Consortium, 2007), complemented with the sequence of
murine EphA2 using the default parameters, including a minimum required length
of seven amino acids per peptide identification, a minimum of one peptide per
protein group identification, carbamidomethylated cystein as a fixed, as well as
oxidated methionine and n-terminal protein acetylation as dynamic modifications.
The match-between-runs feature for ID transfer was enabled. Using the target/
decoy database approach60, the false discovery rate was controlled at 1% for the
peptide and protein groups levels. MaxQuant’s label free quantitation algorithm61
was used to compare bait and control experiments.
Hemotaxylin and Eosin staining. Hemotaxylin and Eosin (H&E) staining was
used for tissues morphological analysis. Mice kidneys, thyroids and inner ears were
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harvested and dehydrated by ethanol, xylene and paraffin. Tissues were embedded
for paraffin sectioning with 10μm tissue sections cut by microtome (Thermo,
HM355S). To deparaffinize and rehydrate, sections were first immersed in xylene
for 3 × 10 min, followed by serial ethanol treatment with 100%, 95%, and 80%
ethanol for 3 × 5 min. Slides were then immersed in deionized water for 5 min. For
hematoxylin staining, tissues were incubated with hematoxylin for 3 min and rinse
in deionized water. Slides were then immersed in tap water to allow staining to
develop. For eosin staining, slides were incubated with eosin for 30–45 s and then
followed by 95 and 100% ethanol washing for 3 × 3 min. After final washing with
xylene for 3 × 5 min, slides were mounted with mounting medium. Nanozoomer
(Hamamatsu Photonics) was used for visualization of H&E staining slides.
Thickness of inner ear stria vascularis and area of thyroid follicular lumen were
measured by NDP.viwer.2 software.
X-ray microtomography. Mice inner ears were isolated and pretreated with 4%
PFA. After washing with PBS, inner ear samples were scanned using SkyScan 1276
microCT imaging system (Bruker). In all, 6424 projection images were acquired
over a 0.5 mm filter with the X-ray source set to 50 kV over a complete 360°
rotation for 1 h. Images were reconstructed using NRecon software. Image pro-
cessing software CTVox was used to generate 3D images and CTAn was used to
measure inner ear cochlear area.
Genetic diagnosis. Genetic screening was performed in two cases using an Invader
assay to screen for 68 known hearing loss-related mutations and direct sequencing
for EPHA2 and SLC26A4 mutations.
Protein structures analysis. Protein domains were analyzed using Pfam62. 3D
protein structures were predicted on the SWISS-MODEL and Phyre2 servers63.
Statistical analysis. All statistical analyses were carried out using Prism software
(Graph Pad, CA). A P < 0.05 was considered statistically significant. Data are based
on at least three independent experiments or three mutant and control animals for
each stage.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The mass spectrometry proteomics data have been deposited in the ProteomeXchange
Consortium via the PRIDE partner repository under the accession code PXD017011. The
source data underlying Figs. 2b, e, g, 3e, 4e, g, h, 5b, d, f, 7a–d and Supplementary
Figs. 2b, 3a, b, d, f, 5b, and 7d are provided as a Source Data file. The remaining data are
available within the article and its supplementary information files and from the
corresponding author on reasonable request.
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